Sager G, Little C
Department of Pharmacology, University of Tromsø, Norway.
Biochem Pharmacol. 1989 Aug 1;38(15):2551-7. doi: 10.1016/0006-2952(89)90101-9.
The plasticizers tris-(2-butoxyethyl)-phosphate (TBEP) and di-(2-ethylhexyl)-phthalate (DEHP) and the beta-adrenergic receptor-blockers [3H]-(-)-dihydroalprenolol ([3H]-(-)-DHA) and [3H]-(-)-CGP 12177 were tested for their ability to interact with beta-adrenergic binding to alpha 1-acid glycoprotein (AAG) and mononuclear leukocytes (MNL). The IC50-values, obtained by displacement of [3H]-(-)-DHA bound to AAG, were 3.5 nM, 2 microM and 4 microM for TBEP, (-)-alprenolol and DEHP, respectively. (+/-)-CGP 12177 had virtually no effect on radioligand binding to AAG. The [3H]-(-)-CGP 12177 binding to MNL consisted of beta-adrenergic receptor binding (Kd = 210 pM) and non-saturable binding. [3H]-(-)-DHA was bound to two different classes of binding sites on MNL, the beta-adrenergic receptors (Kd = 440 pM) and a secondary class of binding sites (Kd = 64 nM). (+/-)-CGP 12177 displaced about 30% of [3H]-(-)-DHA from MNL with an IC50-value of 190 pm. (-)-ALP displaced about 85% of total bound radioligand and gave a biphasic displacement curve with IC50-values of 320 pM and 690 mM, respectively. TBEP displaced a considerable fraction of [3H]-(-)-CGP 12177 and [3H]-(-)-DHA bound to MNL beta-adrenergic receptors, whereas DEHP had no effect. In contrast, DEHP caused displacement of [3H]-(-)-DHA from the MNL low affinity sites, but was a markedly less potent displacer compared to TBEP. The present study shows that TBEP and DEHP interact with beta-adrenergic transport proteins, non-specific tissue binding sites and beta-adrenergic receptors coupled to adenylate cyclase. Plasticizers may thus affect the biology and pharmacology of the beta-adrenergic signal system.
对增塑剂磷酸三(2-丁氧基乙基)酯(TBEP)、邻苯二甲酸二(2-乙基己基)酯(DEHP)以及β-肾上腺素能受体阻滞剂[3H]-(-)-二氢阿普洛尔([3H]-(-)-DHA)和[3H]-(-)-CGP 12177与β-肾上腺素能与α1-酸性糖蛋白(AAG)和单核白细胞(MNL)结合的相互作用能力进行了测试。通过置换与AAG结合的[3H]-(-)-DHA得到的IC50值,TBEP、(-)-阿普洛尔和DEHP分别为3.5 nM、2 μM和4 μM。(±)-CGP 12177对放射性配体与AAG的结合几乎没有影响。[3H]-(-)-CGP 12177与MNL的结合由β-肾上腺素能受体结合(Kd = 210 pM)和非饱和结合组成。[3H]-(-)-DHA与MNL上两类不同的结合位点结合,即β-肾上腺素能受体(Kd = 440 pM)和一类二级结合位点(Kd = 64 nM)。(±)-CGP 12177从MNL上置换了约30%的[3H]-(-)-DHA,IC50值为190 pm。(-)-ALP置换了约85%的总结合放射性配体,并给出了双相置换曲线,IC50值分别为320 pM和690 mM。TBEP置换了与MNLβ-肾上腺素能受体结合的相当一部分[3H]-(-)-CGP 12177和[3H]-(-)-DHA,而DEHP没有影响。相反,DEHP导致[3H]-(-)-DHA从MNL低亲和力位点被置换,但与TBEP相比,其置换能力明显较弱。本研究表明,TBEP和DEHP与β-肾上腺素能转运蛋白、非特异性组织结合位点以及与腺苷酸环化酶偶联的β-肾上腺素能受体相互作用。因此,增塑剂可能会影响β-肾上腺素能信号系统的生物学和药理学特性。